TECH vs. NBIX, QGEN, RGEN, PCVX, RVMD, EXEL, HALO, ARGX, KRYS, and IBRX
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), argenx (ARGX), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Bio-Techne had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 19 mentions for Bio-Techne and 16 mentions for Neurocrine Biosciences. Bio-Techne's average media sentiment score of 1.18 beat Neurocrine Biosciences' score of 0.63 indicating that Neurocrine Biosciences is being referred to more favorably in the media.
Neurocrine Biosciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Neurocrine Biosciences received 596 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.60% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
Bio-Techne has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 4.1% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Neurocrine Biosciences currently has a consensus price target of $150.65, indicating a potential upside of 7.77%. Bio-Techne has a consensus price target of $81.00, indicating a potential upside of 1.77%. Given Bio-Techne's stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Neurocrine Biosciences has a net margin of 18.65% compared to Neurocrine Biosciences' net margin of 17.59%. Bio-Techne's return on equity of 17.45% beat Neurocrine Biosciences' return on equity.
Summary
Neurocrine Biosciences beats Bio-Techne on 13 of the 19 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
